Pacesetter, Inc. — the Abbott subsidiary that carries the former St. Jude Medical cardiac-rhythm business — was granted a US patent on July 7, 2026 that turns an implant’s own accelerometer into a way of catching a mechanical problem clinicians usually only find on imaging. The issued patent, US12672829B2, titled “System for determining change in position of an implanted medical device within an implant pocket,” is directed to detecting when an implant has rotated or flipped inside the surgical pocket where it was placed. Read together with the assignee’s recent grant cohort, it points to a portfolio built around accelerometer-driven diagnostics and leadless cardiac hardware.

The idea in the hero grant is a discrepancy check. An implanted accelerometer records data along at least one axis, and processing logic first establishes when the patient is engaging in an activity associated with a standing posture. During that activity period it identifies the patient’s postures from the accelerometer data. If the sensor reports a non-standing posture while the patient is verifiably upright, and that non-standing reading persists past a duration threshold, the system treats it as evidence that the device itself has moved — because a device that has rotated in its pocket will read the body’s orientation wrong. The disclosure gives a worked example of a 15° rotation as a migration threshold and describes recalibrating a reference standing measurement from x/y/z readings, along with extent-of-right and extent-of-supine tilt parameters and an alert communicated on detection.

The one or more processors are also configured to identify postures of the patient and corresponding posture periods during the activity period based on the accelerometer data, determine a duration related to a non-standing posture identified from the postures identified, and identify a migration of the IMD within the implant pocket based on the duration of the non-standing posture exceeding a duration threshold.— System for determining change in position of an implanted medical device within an implant pocket, US12672829B2

As a portfolio signal, the hero grant fits a clear pattern: use the accelerometer that is already in the device to detect conditions that would otherwise require a clinic visit or imaging. That same instinct shows up directly in US12629104B2, “System for verifying a pathologic episode using an accelerometer,” which uses accelerometer 3D point vectors to verify a candidate arrhythmia episode, and in US12631690B2, directed to detecting abnormal battery consumption due to extra-battery mechanisms — an early-depletion detector. Migration detection, episode verification, and battery-drain detection are three variations on the same theme: the implant reporting on its own physical and operational state.

A leadless-pacemaker instrumentation estate

The rest of the cohort centers on leadless cardiac pacemakers, the miniaturized biostimulators that sit directly in the heart without leads. Three grants describe the hardware itself: US12673211B2, a biostimulator header assembly having an antenna with an embedded antenna loop; US12667731B2, a biostimulator having a flexible circuit assembly built on a folded flex substrate; and US12661501B2, a biostimulator having a resilient scaffold that carries an electrode. These are the antenna, the internal circuit packaging, and the fixation-and-electrode structure of a leadless device — the building blocks of the physical implant.

Stacking the two halves together, the cohort reads as an implantable cardiac-device estate with two reinforcing strands. One strand is the leadless pacemaker as a piece of hardware — antenna, flex circuit, resilient scaffold. The other is a set of accelerometer- and sensor-driven diagnostics that let that hardware, once implanted, monitor whether it has moved, whether it is seeing a real arrhythmia, and whether its battery is draining abnormally. The hero migration-detection grant sits at the intersection: it is a diagnostic that protects the value of the hardware by catching a placement failure early.

For a cardiac-rhythm business, pocket migration is a practical concern — a rotated device can compromise sensing, telemetry, or fixation — and historically it has been diagnosed reactively. A filing directed at surfacing it from routine accelerometer data is consistent with a portfolio that keeps pushing diagnostics into the device rather than the clinic. None of this judges the scope any single claim will ultimately hold, and a grant describes what is claimed, not what has shipped. But across the same recent window, the assignee’s grants line up around one coherent direction: leadless implants that are increasingly instrumented to report on their own position, their own readings, and their own power.

It is worth noting how much of this leans on a single, already-present component. The accelerometer in a leadless pacemaker is there in part for rate-response — adjusting pacing to activity. The cohort repeatedly repurposes that same sensor for secondary diagnostics: posture and orientation for migration, 3D point vectors for episode verification, and, in combination with power monitoring, indirect signals about device health. That reuse is efficient from a design standpoint, because it extracts new clinical information without adding hardware to a device whose defining constraint is size. The hero grant’s migration check is a clean example — it needs no new sensor, only the recognition that a device reading the body’s orientation incorrectly, while the patient’s true posture is independently known, is itself informative. The 15° rotation example and the recalibration of a standing reference from x/y/z readings show the disclosure working out how to separate a genuine device shift from ordinary measurement noise.

Taken as a group, these six grants describe both the object and its senses — the small device that goes into the heart and the accelerometer logic that lets it notice when something about its placement or operation has changed. The migration-detection patent is a single issued record, but as a window into the estate it signals where the design attention sits: on making a leadless implant self-aware enough to flag its own mechanical drift.